Strontium-89: Clinical Trials

5 trials of Strontium-89, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 terminated. 3 Phase 2, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 23Completed 2, Terminated 1
Phase 32Completed 1, Terminated 1

Follow Strontium-89: new trials by email Literature Review of Strontium-89 trials Research Report on Strontium-89

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
Calcium, Vitamin D, zoledronic acid - Breast Cancer, Lung Cancer
Phase 3CompletedRadiation Therapy Oncology Group2612006-07-112024-09-20
Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
Doxorubicin hydrochloride, Goserelin acetate, Leuprolide acetate - Metastatic Cancer, Prostate Cancer
Phase 2CompletedM.D. Anderson Cancer Center802004-07-012016-11-10
A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer
strontium-89, cisplatin - Hormone Refractory Prostate Cancer, Bone Metastases
Phase 2CompletedAlberta Health services582003-08-012012-01-19
Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
Docetaxel, Doxorubicin hydrochloride, Estramustine phosphate sodium - Prostate Cancer
Phase 3TerminatedM.D. Anderson Cancer Center2652002-04-012016-03-22
Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases
Celecoxib, Doxorubicin Hydrochloride, Strontium chloride Sr 89 - Metastatic Cancer, Prostate Cancer
Phase 2TerminatedM.D. Anderson Cancer Center142002-02-012018-10-31

Conditions studied

Prostatic Neoplasms (5)  ·  Neoplasm Metastasis (3)  ·  Breast Neoplasms (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Lung Neoplasms (1)  ·  Pain (1)

Sponsors

M.D. Anderson Cancer Center (3)  ·  Alberta Health services (1)  ·  Radiation Therapy Oncology Group (1)

Countries

United States (4)  ·  Canada (1)

Top investigators

Shi-Ming Tu, MD (3)  ·  Bernie Eigl, MD (1)  ·  Jackson Wu (1)  ·  Michael J. Seider, MD, PhD, FACR (1)

Results publications

PMID 16258090, PMID 30094545

NIH funding

P30CA016672 (2), U10CA045809 (2), P50CA090270 (1)